International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Quality Assurance and Quality Control

Vaibhav Ramdas Jadhav[1], Akanksha Madhukar Purkar[2], Nikita Santosh Dukale[3], Bhushan Pravin Gaikwad[4], Dipali Ramdas Jadhav[5]

[1,2,3,4]Final Year B.Pharmacy, Swami Institute Of Pharmacy, Abhona, Nashik
[5]Third Year B.Pharmacy, Swami Institute Of Pharmacy, Abhona, Nashik

Abstract

This review offers an overview of Quality Assurance (QA) and Quality Control (QC) in the pharmaceutical industry, highlighting their vital roles in ensuring the safety, efficacy, and reliability of products. QA involves preventing defects and ensuring quality throughout a product's lifecycle, while QC focuses on identifying and correcting defects through testing. Key regulatory frameworks like Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP), and International Council for Harmonisation (ICH) guidelines are discussed, along with Good Warehousing Practices (GWP) for storage integrity. The document covers drug discovery and development, validation processes, and the roles of regulatory authorities such as the FDA, WHO, and MHRA. It concludes by introducing Quality by Design (QbD) and Process Analytical Technology (PAT) as methods for embedding quality from the start.

Introduction

Quality Assurance (QA) and Quality Control (QC) are two distinct but interconnected components crucial to ensuring pharmaceutical products' safety, efficacy, and reliability.

Quality Assurance : According to WHO, quality assurance is a wide- ranging concept covering all matters that individually or collectively influence the quality of a product. With regard to pharmaceuticals, quality assurance can be divided into major areas: development, quality control, production, distribution, and inspections.[1, 2]

ISO 9000 defines as "part of quality management focused on providing confidence that quality requirements will be fulfilled" [3]

Quality Control

ISO 9000 defines quality control as "A part of quality management focused on fulfilling quality requirements". It is that part of GMP concerned with sampling, specification & testing, documentation & release procedures which ensure that the necessary & relevant tests are performed & the product is released for use only after ascertaining its quality.[3 ,4]

QC is a set of activities for ensuring quality in products. The activities focus on identifying defects in the actual products produced. QC is a corrective tool.

Good Laboratory Practices (GLP)

Good laboratory Practices (GLP) is a set of guidelines that govern the process, organization and conditions

under which laboratory studies are conducted.

Good Laboratory Practices are defined by the Organization for Economic Cooperation and Development (OECD) as a set of rules and criteria for quality systems concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, reported, and archived.[5]

GLP is defined by principles that provide a framework within which laboratory studies are planned, performed, monitored, recorded, reported and archived.

General Provisions

Scope:

1. Good Laboratory Practices should be applied to the non-clinical safety testing of test items contained in pharmaceutical products, cosmetics products, veterinary drugs as well as food additives, feed additives, and industrial chemicals.
2. The tests items are mostly synthetic chemicals having natural or biological origin or living organisms.
3. The purpose of testing is to get data on their properties and their safety with respect to human health.

Objectives:

1. GLP provides the data submitted are accurate from the results which are obtained during course of the study.
2. Data obtained is a traceable.
3. There is an international acceptance of tests.

Organization and Personnel:

Organization: - Performance of numerous quality oriented tasks or quality control work elements is required to achieve quality in the product. Organizing of quality is the identification of the essential quality control work elements and assignment of responsibility for getting done. USFDA **GLP** require that testing facility management should designate a study director for each non-clinical laboratory study.

TOP Management:

- To develop company quality plan for achieving the company goals.
- To develop company quality objectives.
- To design organizational structure.
- To design system of product quality evaluation, audits, surveillance.

Head of Quality Control department:

- Evaluation of batch record.
- Approval or rejection of starting material, packaging material, bulk and finished products.
- Approval of quality control procedures, instruction, test methods
- Maintenance of manufacturing and testing environment
- Maintenance of records.
- Maintenance of premises, equipment, department.

Personnel

The responsibilities of all personnel should be defined and recorded in job descriptions and their qualifications and competence defined in education and training records. To maintain adequate levels of competence, GLP attaches considerable importance to the qualifications of staff, and to both internal and external training given to personnel.

The Study Director who controlling the whole study. This person is appointed by the test facility management and will assume full responsibility for the GLP compliance of all activities within the study.
Principles of GLP:-These principles apply to the non-clinical safety testing of substances found in various products to ensure the quality and integrity of the safety data submitted to regulatory authorities globally.[5]

1. Quality Assurance Program.
2. Facilities
3. Apparatus material and reagents.
4. Test system
5. Test and reference items
6. Standard Operating Procedure (SOP's)
7. Performance of the Study
8. Reporting of the study result.

Good Manufacturing Practices:- Good Manufacturing Practices (GMP, also referred to as 'cGMP' or 'current Good Manufacturing Practice') is the aspect of quality assurance that ensures that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the product specification.
GMP defines quality measures for both production and quality control and defines general measures to ensure that processes necessary for production and testing are clearly defined, validated, reviewed, and documented, and that the personnel, premises and materials are suitable for the production of pharmaceuticals and biological including vaccines. GMP also has legal components, covering responsibilities for distribution, contract manufacturing and testing, and responses to product defects and complaints.[18]

Principles of GMP

1. Quality management
2. Personnel
3. Documentation
4. Production areas.
5. Quality control
6. Complaint and product recall
7. Self-inspection

GMP Requirements

GMP regulations require a quality approach to manufacturing enabling companies to minimize or eliminate instances of contamination, mix-up, or errors.

5P's Of GMP

1.People 2. Premises 3.Products 4.Procedures 5.Processes

ICH Guideline

The International Council for Harmonization (ICH), established as a legal entity under Swiss law on 23 October 2015, builds on 25 years of successful efforts to harmonize global pharmaceutical development and regulation. ICH works to ensure the quality, safety, and efficacy (QSE) of drugs by bringing together regulatory experts and pharmaceutical industry partners from regions like the European Union, Japan, and the United States. Its guidelines, which cover quality, safety, efficacy, and multidisciplinary areas, provide standardized requirements for drug testing and development, promoting global consistency in drug regulation.

ICH Guidelines

1. Quality Guidelines (Q1 to Q11):

Q1A (R2): Stability testing of New Drug substances and products.

Q2. : Stability testing: Photostability Testing of New Drug Substance and Drug Product.
Q1C: Stability testing of New Dosage form.
Q1D: Bracketing and Matrixing Designs for Testing of New Drug Substance and Products.
Q1E: Evaluation of Drug Stability Data
Q1F: Stability Data Package for Registration Application in Climatic Zones III and IV.
Q2 Analytical Validation
Q3A-Q3E Impurities
Q3A (R2): Impurities in New Drug Substance
Q3B (R2): Impurities in New Drug Product
Q3C (R9): Guidelines in residual solvents.
Q3C (R10) : Maintenance of EWC
Pharmacopeia
Q4A: Pharmacopoeial Harmonization
Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
Q5: Quality of Biotechnological Products
Q6A-Q6B: Specifications
Q6A: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products, Chemical Substances
Q6B: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
Q7: Good Manufacturing Practices In February 1998, the ICH Steering Committee agreed that GMP for Active Pharmaceutical Ingredients (APIs) should be adopted as an ICH Topic.
Q8: Pharmaceutical Development This annex describes the principles of quality by design (QbD).
Q9: Quality Risk Management: This Guideline provides principles and examples of tools of QRM that can be applied to all aspects of Pharmaceutical quality including development, manufacturing, distribution, And the inspection and submission/review processes throughout the Lifecycle of drug substances and drug (medicinal) products, biological and Biotechnological products, including the use of raw materials, solvents, Excipients, packaging and labelling materials.
Q10: Pharmaceutical Quality System: This Guideline applies to pharmaceutical drug substances and drug products, including biotechnology and biological products, throughout Product lifecycle.
Q11: Development and Manufacture of Drug Substance :This new guidance is proposed for Active Pharmaceutical Ingredients (APIs) harmonizing the scientific and technical principles relating to the description and justification of the development and manufacturing process.
Q12: Lifecycle Management This new guideline is proposed to provide guidance on a Framework to facilitate the management of post-approval Chemistry, Manufacturing and Controls (CMC) changes in a more predictable and efficient manner across the product lifecycle. Adoption of this new ICH Guideline will promote innovation and continual improvement, and strengthen Quality assurance and reliable supply of product, including proactive planning of supply chain adjustments. [6]

2. Safety Guidelines (S1-S10,M3)

ICH has produced a comprehensive set of safety guidelines to uncover potential risks like carcinogenicity, nontoxicity and nephrotoxicity.
A recent breakthrough has been a non-clinical testing strategy for assessing the QT interval prolongation liability: the single most important cause of drug withdrawals in recent years.
SIA-SIC: Carcinogenicity Studies

S2: Geno-toxicity Studies
S3A-S3B: Toxic kinetics and Pharmacokinetics
S4: Toxicity Testing
S5: Reproductive Toxicology
S6: Biotechnological Products
S7A-S7B: Pharmacology Studies
S8: Immunotoxicological Studies
S9: Nonclinical Evaluation for Anticancer Pharmaceuticals $10: Photo safety Evaluation
S11: Nonclinical Pediatric Safety [7]

3. Efficacy Guidelines (E1-E16 Except E13)

The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials. It also covers novel types of medicines derived from biotechnological processes and the use of pharmacokinetics/ pharmacogenomics techniques to produce better targeted medicines.

E1: Clinical Safety for Drugs used in Long-Term Treatment
E2A-E2F: Pharmacovigilance
E3: Clinical Study Reports
E4: Dose-Response Studies
E5: Ethnic Factors
E6: Good Clinical Practice
E7: Clinical Trials in Geriatric Population
E8: General Considerations for Clinical Trials
E9: Statistical Principles for Clinical Trials
E10: Choice of Control Group in Clinical Trials
E11: Clinical Trials in Pediatric Population
E12: Clinical Evaluation by Therapeutic Category
E14: Clinical Evaluation of QT
E15: Definitions in Pharmacogenetics/ Pharmacogenomics
E17: Multi-Regional Clinical Trials
E18: Genomic Sampling
E19: Safety Data Collection.
E20: Adaptive Clinical Trials.
E21: Inclusion of pregnant and breast feeding individuals in clinical.
E22: General consideration to patient preference studies.[8]

4. Multidisciplinary Guidelines (M1-M8)

Those are the cross-cutting topics which do not fit uniquely into one of the Quality, Safety and Efficacy categories. It includes the ICH medical terminology (MedDRA), the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI).s

M1: MedDRA Terminology
M2: Electronic Standards.
M3: Nonclinical Safety Studies
M4: Common Technical Document.

M5: Data Elements and Standards for Drug Dictionaries
M6: Gene Therapy M7: Mutagenic impurities
M8: Electronic Common Technical Document (eCTD)
M9: Biopharmaceutics Classification System-based Bio waivers
M10: Bio-analytical Method Validation
M11: Clinical electronics Structured Harmonized Protocol (CESHARP)
M12: Drug Interaction Studies
M13: Bioequivalence studies for immediate release solid dosage form.
M14: Use of real world data for safety assessment of medicines
M15: General information for model informed drug development.[9]

Good warehousing practices

Good warehousing practices in the pharmaceutical industry are critical to ensuring product safety, efficacy, and regulatory compliance. The sensitive nature of pharmaceutical products, which often require strict controls on storage conditions and handling, makes robust quality assurance (QA) and quality control (QC) measures essential [10]

Purpose of Good Warehousing Practices in Pharmaceuticals

1. **Product Safety:** Protects against contamination and degradation of pharmaceutical products.
2. **Regulatory Compliance:** Ensures adherence to laws and regulations, minimizing legal and financial risks.
3. **Quality Assurance:** Maintains the efficacy and safety of drugs throughout their shelf life.
4. **Traceability**: Enables tracking of products from manufacturing to end-user, essential for recalls and quality assessments.

Guidelines and Principles

1. Facility Design and Layout

Controlled Environment: Warehouses should be designed with environmental controls (temperature, humidity, air quality) suitable for pharmaceutical products.

Zoning: Establish separate zones for different categories (e.g., controlled substances, hazardous materials, temperature-sensitive products) to prevent cross-contamination.

Cleanliness: Regular cleaning protocols must be in place to maintain hygiene.

2. Storage Conditions

Temperature and Humidity Control: Use validated monitoring systems to maintain required storage conditions (e.g., refrigeration for biologics). Ensure continuous monitoring and alarms for temperature deviations.

Secure Storage: Controlled substances and sensitive items must be stored in secured areas with restricted access.

3. Inventory Management

FIFO and FEFO Practices: Implement First-In-First-Out (FIFO) and First-Expiry-First-Out (FEFO) systems to minimize waste and ensure older products are used first.

Automated Inventory Systems: Use electronic inventory management systems to track stock levels, expiry dates, and reorder points.

4. Handling Procedures

Training Programs: Provide regular training for staff on proper handling and storage of pharmaceuticals, focusing on safety and quality.

Personal Protective Equipment (PPE): Ensure staff wear appropriate PPE when handling hazardous drugs or materials.

5. Quality Control Checks

Incoming Quality Inspections: Conduct rigorous inspections of all incoming pharmaceutical products to verify compliance with specifications and quality standards.

Ongoing Quality Monitoring: Implement regular audits and checks of stored products to ensure they remain within required quality parameters.

6. Documentation and Record Keeping

Standard Operating Procedures (SOPs): Develop detailed SOPs for all warehousing activities, including receiving, storage, and distribution.

Batch Records and Traceability: Maintain accurate records of batch numbers, storage conditions, and movement history to facilitate traceability and compliance with regulatory requirements.

7. Regulatory Compliance

Compliance with Standards: Adhere to regulations such as Good Distribution Practices (GDP), FDA regulations, and European Medicines Agency (EMA) guidelines.[10]

Licensing and Audits: Ensure the warehouse is properly licensed and undergoes regular

In-Process Quality Control Process (IPQC)

- IPQC is concerned with providing accurate, specific, and definite descriptions of the procedures to be employed, from the receipt of raw materials to the release of finished dosage forms.
- In process Quality Control, IPQC tests are mostly performed within the production area.
- They should not carry any risk for the quality of product.
- In process testing enables easier identification of problems.
- It sometime identifies a defective product batch that can be corrected by rework, whereas once that batch has been completed, this may not be possible.
- Failure to meet in process control specification indicates either that procedure were not followed or some factor (S) out of control.

Instrument used in IPQC department

1. Disintegration apparatus
2. Dissolution apparatus
3. Analytical balance
4. Muffle Furnace
5. Friability testing apparatus
6. Bulk density apparatus
7. Tablet hardness tester
8. Infra-red moisture content measuring apparatus
9. Abbe Refractometer
10. U.V Spectroscopy

Official and Unofficial Tests for Evaluation of tablets

Official Tests

1. Color and Odor
2. Unique Identification Markings
3. Weight variation
4. Disintegration Time
5. Dissolution
6. Content Uniformity [11,12]

Non-Official Tests

1. Hardness
2. Friability
3. Thickness
4. Leakage testing for strip and blister packaging

Test for Capsules

1. Uniformity of Content
2. Disintegration Test
3. Weight Variation Test
4. Dissolution test [10]
5. Moisture Permeation Tests.[11]

Tests for Ointment and Creams

1. Weight Variation Test
2. Consistency
3. Identification of active contents
4. Assay of active contents
5. Melting point
6. Solubility
7. Microbial Contamination Test[11,19]

Tests for Suppositories

1. Test of Appearance
2. Uniformity of weight
3. Breakage Test (Test of physical strength)
4. Content uniformity test
5. Disintegration Test
6. Test of Dissolution Rate
7. Test of Melting Range or Melting point determination test
8. Liquefaction time (softening)
9. Assay of active contents
10. Test of drug uptake/ absorption in to blood stream
11. Stability Problems of Suppositories [11]

IPQC Tests for Parenteral

1. Conductivity Measurement
2. Volume filled
3. Temperature for heat sterilized product

4. Osmolarity
5. Environmental control test
6. pH Measurement [13,15]

FPQC Tests for Parenteral

1. Content uniformity Test
2. Leaker Test
3. Pyrogen Test
4. Sterility Test
5. Particulate Test[13,15]

Tests for Ophthalmic preparation

1. Sterility Test
2. Clarity Test
3. Leaker Tests
4. Metal particles in ophthalmic ointments [13]

IPQC Tests for Surgical Products

1. Sterility Testing
2. Physical Testing (e.g., strength, dimensions)
3. Impurity Profile Testing
4. Viscosity and Rheological Testing
5. Particle Size Distribution
6. Microbiological Testing
7. Environmental Monitoring

FPQC Tests for Surgical Products

1. Sterility Testing
2. Endotoxin (Pyrogen) Testing
3. Package Integrity Testing
4. Identity, Purity, and Strength Testing
5. Dimensional and Mechanical Testing
6. Biocompatibility Testing
7. Chemical Testing

Regulatory Authorities

1. Food and Drug Administration (FDA)

The **FDA**, or **Food and Drug Administration**, is a U.S. government agency that plays a key role in protecting public health. It is responsible for regulating and overseeing a wide range of products, including food, drugs, medical devices, cosmetics, and more. The FDA ensures that these products are safe, effective, and properly labeled for consumers.[14]

Functions of FDA

Regulating Food Safety:

- Ensures food products are safe, nutritious, and properly labeled.
- Oversees food additives, ingredients, and packaging materials.
- Sets standards for food labeling to provide consumers with essential information (e.g., nutritional content, allergens).

- Monitors food production, manufacturing, and distribution to prevent contamination.
- Conducts food recalls when necessary to protect public health.[14]

Regulating Drugs:

- **Approval of New Drugs**: Reviews and evaluates the safety, efficacy, and quality of new pharmaceutical drugs (prescription and over-the-counter).
- **Clinical Trials**: Sets guidelines for clinical trials and oversees the development of drugs before they are marketed.
- **Post-market Surveillance**: Monitors drugs after approval to ensure they remain safe for public use through adverse event reporting systems.
- **Generic Drugs**: Approves and regulates generic drugs to ensure they are equivalent to brand-name drugs in terms of safety, effectiveness, and quality.
- **Drug Labeling**: Ensures that drugs are accurately labeled with proper instructions, dosage information, and warnings.[14]

Regulating Medical Devices:

- **Device Approval**: Regulates the safety and efficacy of medical devices, from simple bandages to complex devices like pacemakers and MRI machines.
- **Risk Classification**: Classifies medical devices into three categories (Class I, II, III) based on their risk level to consumers, with varying levels of regulatory scrutiny.
- **Device Monitoring**: Monitors devices post-market for safety and performance, conducting recalls when necessary.
- **Device Labeling**: Ensures that medical devices are labeled appropriately to inform healthcare professionals and consumers about their proper use and risks.[14]

Regulating Biologics:

- **Vaccines and Blood Products**: Ensures the safety, efficacy, and purity of vaccines, blood products, and other biologics (e.g., gene therapies, monoclonal antibodies).
- **Approval and Monitoring**: Reviews clinical data before approving biologics for public use and conducts ongoing monitoring for safety after approval.[14]

Regulating Cosmetics:

- Ensures that cosmetics (including skincare, hair care, and makeup products) are safe for use and properly labeled.
- Monitors the use of ingredients in cosmetics to prevent harmful substances from being included.
- Does not approve cosmetics before they are marketed, but can take action against unsafe products in the marketplace.[14]

Regulating Tobacco Products:

- Regulates tobacco products, including cigarettes, smokeless tobacco, and e-cigarettes, to reduce public health risks.
- Oversees the marketing, sale, and distribution of tobacco products, especially with regard to preventing youth access.
- Administers the **Family Smoking Prevention and Tobacco Control Act**, which gives the FDA authority over tobacco products.[14]

Regulating Dietary Supplements:

- Ensures that dietary supplements (e.g., vitamins, minerals, herbs) are safe and accurately labeled.

- Monitors the manufacturing practices of dietary supplements to ensure they meet safety standards.
- Does not approve dietary supplements before they are marketed, but can intervene if a product is found to be unsafe or mislabeled.[14]

Regulating Animal Drugs and Feeds:

- **Animal Drugs**: Regulates drugs and treatments used for animals, ensuring they are safe and effective.
- **Animal Feed**: Ensures that animal feed is safe and nutritious, and that it does not contain harmful substances that could affect animal health or human consumers.
- Works with the **Center for Veterinary Medicine (CVM)** to oversee animal health products and protect both animal and human health.

Emergency Response and Public Health Protection:

- Responds to public health emergencies, such as disease outbreaks, natural disasters, or bioterrorism events (e.g., the FDA played a key role during the COVID-19 pandemic).
- Provides emergency use authorizations (EUAs) for drugs, vaccines, and medical devices during public health emergencies.
- Coordinates with other agencies, such as the Centers for Disease Control and Prevention (CDC), in emergency situations.[14]

Regulating Digital Health Technologies:

- Approves and monitors digital health technologies, such as mobile health apps, telemedicine tools, and artificial intelligence-based medical devices.
- Focuses on ensuring that these technologies meet safety, effectiveness, and privacy standards.[14]

2. World Health Organization (WHO)

The **World Health Organization (WHO)** is a **specialized agency of the United Nations** (UN) responsible for international public health. Established in 1948, the WHO's mission is to promote health, keep the world safe, and serve the vulnerable. It works to ensure universal access to essential healthcare, the prevention of disease, and global health standards.[20,21]

Responsibilities of the WHO

1. Setting Global Health Standards:

The WHO develops and sets **international health standards** for diseases, medicines, and healthcare practices. This includes guidelines on **vaccines**, **medicines**, **sanitation**, and **healthcare systems**. It also provides **technical support** to countries in need.

2. Health Research:

The WHO is responsible for conducting and coordinating **health research** to understand diseases and improve treatment. It also monitors and tracks global health trends such as emerging diseases, health disparities, and population health.

3. International Disease Surveillance:

One of WHO's core functions is **disease surveillance** and **monitoring**. This includes managing **global health emergencies**, responding to **outbreaks** (such as COVID-19), and tracking ongoing diseases like **HIV/AIDS**, **malaria**, and **tuberculosis**.

4. Health Systems Strengthening:

WHO works to support **health systems** in developing and low-resource countries, helping them build infrastructure, train health workers, and ensure access to essential health services.

5. **Emergency Response and Humanitarian Aid**:
WHO plays a central role in responding to **health emergencies**, both natural (e.g., earthquakes, floods) and man-made (e.g., conflict zones), providing medical supplies, advice, and guidance.
6. **Global Policy and Advocacy**:
The WHO advocates for global health policies, **health equity**, and sustainable development. It works with **governments**, **NGOs**, and international organizations to shape policy that addresses global health challenges.
7. **Regulation and Safety Standards**:
In collaboration with other international bodies like the **International Labour Organization (ILO)** and the **World Trade Organization (WTO)**, the WHO sets international safety standards for pharmaceuticals, vaccines, and medical devices. For example, it helps in setting guidelines on **Good Manufacturing Practices (GMP)** and **Good Clinical Practices (GCP)**, and it works with **regulatory agencies** such as the **European Medicines Agency (EMA)** and **MHRA** to monitor the safety of health products worldwide.[20]

3. Medicines and Healthcare products Regulatory Agency (MHRA):-
The **MHRA** stands for the **Medicines and Healthcare products Regulatory Agency**. It is a UK government agency responsible for ensuring that medicines, medical devices, and other healthcare products are safe and effective for use. The MHRA regulates the manufacturing, distribution, and use of these products in the UK, working to protect public health.[21]

Responsibilities of the MHRA include:

1. **Regulating Medicines and Medical Devices**: Ensuring they meet safety standards and perform as intended.
2. **Licensing**: Issuing marketing authorizations for medicines and medical devices, including ensuring that clinical trials are conducted ethically.
3. **Pharmacovigilance**: Monitoring the safety of medicines and medical devices once they are on the market, investigating adverse reactions and making necessary safety recommendations.
4. **Enforcement**: Taking action against non-compliant products or manufacturers, including recalling products or issuing warnings. [21]

4.Therapeutic Good Administration (TGA)
The **TGA** stands for the **Therapeutic Goods Administration**, which is Australia's regulatory authority for medicines, medical devices, and other therapeutic goods. It is part of the **Australian Government Department of Health** and is responsible for ensuring the safety, efficacy, and quality of therapeutic products available in Australia. The TGA operates in a similar way to other international regulatory bodies, such as the **European Medicines Agency (EMA)** and the **U.S. Food and Drug Administration (FDA)**, but with a focus on protecting Australian public health.[22]

Responsibilities of the TGA
Regulation of Medicines and Medical Devices:

- The TGA is responsible for the regulation of **therapeutic goods**, including **medicines** (prescription, over-the-counter, and complementary medicines) and **medical devices** (e.g., implants, diagnostic devices). It ensures that these products meet the required standards of **quality**, **safety**, and **efficacy**

before they can be sold in Australia.

- The TGA's approval process includes a thorough **assessment of clinical data**, **manufacturing practices**, and **product labeling** to ensure that therapeutic goods are suitable for use by the public.

Product Registration:

- Before a therapeutic good can be marketed in Australia, it must be **registered** with the TGA. This involves submitting a dossier with detailed information on the product's **safety** and **effectiveness**.
- For **medicines**, this typically involves evidence from **clinical trials** and other scientific data to demonstrate that the product works as intended and is safe for the intended population.
- For **medical devices**, the TGA evaluates the device's **design**, **function**, and **safety**. Devices are classified according to their risk level, and the approval process varies depending on the class of device.

Pharmacovigilance (Monitoring of Safety):

- Once medicines and medical devices are approved for use in Australia, the TGA continues to monitor their **safety**. This process is known as **pharmacovigilance**.
- The TGA runs systems such as the **Adverse Event Reporting System**, which allows healthcare professionals and the public to report any adverse reactions or side effects related to therapeutic goods.
- The TGA also works with other international regulatory bodies to monitor the global safety of therapeutic products and to take action when safety concerns arise. This can include **product recalls**, **warnings**, and **labeling changes**.

Post-Market Surveillance:

- The TGA conducts regular inspections and audits of **manufacturing facilities** and **clinical trial sites** to ensure compliance with Australian regulations.
- The TGA also carries out **post-market surveillance** to assess the ongoing safety and effectiveness of products once they are on the market, including reviewing the **adverse event reports** and evaluating real-world data.

Therapeutic Goods Advertising:

- The TGA regulates the **advertisement** of therapeutic goods to ensure that claims made about medicines and medical devices are truthful and not misleading.
- It has guidelines that set the standards for advertising to both healthcare professionals and the general public. Ads must not overstate benefits or minimize risks.

Regulatory Standards and Guidance:

- The TGA provides guidelines and regulations for the **manufacturing**, **importation**, and **sale** of therapeutic goods in Australia. This includes standards for GMP**,** which ensures that products are consistently produced and controlled according to high standards of quality.
- It also works to align Australian standards with **international standards** for the regulation of therapeutic products, collaborating with global organizations like the **World Health Organization (WHO)** and **International Council for Harmonization (ICH)**

Emergency and Crisis Management:

- In times of **public health emergencies** or **crises**, such as during the COVID-19 pandemic, the TGA can fast-track the approval of certain medicines and medical devices to ensure that life-saving products are available to the public.
- It is involved in making decisions regarding the **emergency use authorization** of vaccines and treatments during outbreaks.

Regulation of Complementary Medicines:

- In addition to conventional medicines, the TGA is also responsible for the regulation of **complementary medicines** (e.g., vitamins, herbal products, and supplements). These products are subject to different regulations, but the TGA still ensures that they meet certain standards for safety, quality, and efficacy.[22]

Documentation in pharmaceutical Industry:

Standard Operating Procedures (SOP's)

Step 1: Begin with the end in mind....
Step 2: Choose a format.
Step 3: Ask for input.....
Step 4: Define the scope.....
Step 5: Identify your audience....
Step 6: Write the SOP….
Step 7: Review, test, edit, repeat.

Master Batch Record :-A master batch record (MBR), also known as a master production record (MPR) is a document that contains the approved ingredients, formulation, and instructions guiding the production of a pharmaceutical product.

Batch Manufacturing Record: - It is a written record that documents the entire manufacturing process and the history of a product batch. In other words, it tells you how to produce a product and records the way that happens.

Quality audit plan: - Quality audit are programs designed to verify or examine a product or manufacturing process over time. These can be classified as manufacturing quality audits, sanitation/GMPs audits, HACCP audits, product quality audits and other special types of audits. A quality audit is a fundamental part of quality assurance (QA) programs. It allows for quality verification of a product during manufacture, in the warehouse, in the distribution system, and in the market to assess performance overtime or for comparison to competitor brands.

Drug Master File submission: -

A Drug Master File (DMF) is a submission to the FDA of information, usually concerning the confidential detailed information about Chemistry Manufacturing and Controls (CMC) of a drug product or a component of a drug Product. Other non CMC - information (like packaging, storing) may also be filed in a DMF.

Type I-Manufacturing sites, facilities, operating procedure, and personnel
Type II-Drug substance, drug substance intermediate, and materials used in their preparation, or drug product
Type III-Packaging material
Type IV-Excipient, colorant, flavor, essence, or material used in their preparation
Type V-FDA-accepted reference information

M4 Common Technical Document (CTD)

The Common Technical Document (CTD) is a set of specifications for the registration of medicines, developed by the European Medicines Agency, FDA, and Japan's Ministry of Health, Labour, and

Welfare. It is an internationally agreed format for NDA submitted to regional regulatory authorities. The CTD has revolutionized regulatory review processes by assembling all Quality, Safety, and Efficacy information in a common format. It is organized into five modules, with Module 1 being region-specific and Modules 2, 3, 4, and 5 being common for all regions. In 2003, the CTD became mandatory for NDA in the EU and Japan.[16,17,18,23]



Electronic Common Technical Document (eCTD) The eCTD is the standard format for submitting applications, amendments, supplements, and reports to FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER)

Types of Submission Subject to eCTD requirements

Electronic submission requirements will apply to the following types of submissions to CDER/CBER:

- NDAs
- ANDAs
- BLAs
- Commercial IND applications (for products that are intended to be distributed commercially)
- All subsequent submissions to these types of applications, including amendments, supplements, and reports, even if the original submission was filed before the requirements went into effect
- Master files, such as DMFs, which are considered to be submissions to an IND, an NDA, an ANDA, or a BLA
- Electronic submission standards will be optional but encouraged for the following categories:
- Noncommercial INDs, such as investigator-sponsored INDs and expanded-access INDs
- Submissions for blood and blood components, including source plasma
- Submissions for Type III Master Files[23]

Concept of regulated and non-regulated markets:-

Regulated Market:

In regulated markets, countries have well-established guidelines for the approval, marketing, and distribution of pharmaceutical products for both human and veterinary use. Marketing Authorization Holders (MAHs) must submit applications to the relevant authorities to obtain approval for their drugs, supported by comprehensive and required documentation. Examples of such regulated markets include major countries with dedicated regulatory agencies to oversee public health, such as the United States, Japan, Australia, Canada, and India. In these markets, the submission of a drug dossier in the CTD format is mandatory, which must include clinical trial data and bioequivalence studies.

Non-Regulated Market:

Non-regulated markets are typically found in smaller or less-developed countries that do not have dedicated regulatory authorities to manage the distribution and supply of medicines. These can include newly established nations, countries with small populations, and underdeveloped regions, such as some African and Asian countries. In the absence of local monitoring bodies, these markets often depend on the regulatory frameworks of more established, regulated countries to ensure the safety and quality of pharmaceutical products.

5. Introduction to principles of Drug discovery and development

Drug discovery and development is a multi-step, rigorous process that involves the identification of new potential drug compounds, followed by preclinical and clinical testing to ensure their safety and efficacy, and finally, regulatory approval before they can be marketed. The process can take years and involves collaboration across several domains, including biology, chemistry, pharmacology, and clinical medicine. The process is generally divided into several phases:

1. Drug Discovery
2. Preclinical Testing
3. Clinical Trials
4. Regulatory Approval
6. Post-marketing Surveillance

Each phase involves a series of decisions based on both scientific evidence and regulatory requirements to ensure the drug is safe and effective for use in humans.

Clinical Research Process

Clinical research is the phase in which the drug is tested on human subjects. This involves a carefully designed sequence of stages, usually divided into four phases:

1. Preclinical Phase

Laboratory Research: Before a drug is tested on humans, it undergoes laboratory research to determine its chemical composition, mechanisms of action, and potential biological effects.

Animal Testing: Animal studies help determine how the drug behaves in a living organism, its safety, toxicity levels, and the appropriate dosage range.[17]

2. Phase 1 Clinical Trials

Objective: Test the drug's safety in a small group (20-100) of healthy volunteers.

Purpose: Determine the drug's pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted) and pharmacodynamics (its biological effects).[17]

3. Phase 2 Clinical Trials

Objective: Test the drug's effectiveness and side effects in a larger group (100-300) of patients who have the condition the drug is designed to treat.

Purpose: Establish the therapeutic dosage, monitor for side effects, and assess early signs of efficacy. [17]

4. Phase 3 Clinical Trials

Objective: Further evaluate the drug's effectiveness in a much larger population (1000-3000) of patients.

Purpose: Confirm the drug's efficacy, monitor side effects in diverse populations, and compare it with current standard treatments. [17]

5. Phase 4 (Post-Marketing Surveillance)
Objective: Ongoing studies after the drug is approved for public use.
Purpose: Monitor long-term effects, rare side effects, and overall safety in the general population. [17]

Regulatory Approval Process:-After the clinical trials, a company submits detailed data on the drug's safety, efficacy, and quality to regulatory agencies for approval. Several key documents and regulatory submissions are involved in this process:

1. Investigational New Drug (IND) Application
Purpose: The IND is the document submitted to regulatory authorities (such as the FDA in the US) to gain approval to begin human clinical trials.
Content: Includes preclinical data, clinical trial protocols, investigator information, and the drug's chemical composition. It ensures that the proposed studies will be safe for human participants.

2. New Drug Application (NDA)
Purpose: Once clinical trials (Phase 1, 2, and 3) are completed and the drug demonstrates safety and efficacy, the manufacturer submits an NDA for approval to market the drug.
Content: The NDA includes results from clinical trials, manufacturing processes, labeling, and details of the proposed indication for the drug.
Outcome: The FDA reviews the NDA, and if approved, the drug is granted permission to be marketed.

3. Abbreviated New Drug Application (ANDA)
Purpose: The ANDA is a submission for generic drugs, allowing manufacturers to apply for approval to market a drug that is bioequivalent to an already-approved branded drug.
Content: Includes evidence that the generic product is equivalent in terms of dosage form, strength, route of administration, and bioavailability.

4. Supplemental New Drug Application (SNDA)
Purpose: The SNDA is filed if there are any changes to an existing drug post-approval. This could include changes in formulation, labeling, or manufacturing processes.
Content: The SNDA includes data to support changes, ensuring that the drug remains safe and effective despite the adjustments.

5. Scale-Up Post Approval Changes (SUPAC*)*
Purpose: SUPAC guidelines are intended to address changes in the manufacturing process after a drug has been approved. For example, if a manufacturer changes the production scale, the product formulation, or production process, a SUPAC filing is required to demonstrate that these changes do not affect the drug's quality, safety, or efficacy.
Content: SUPAC filings include data on batch consistency, stability, and the effect of scale-up on the final product.

6. Bulk Active Chemical Post Approval Changes (BACPAC)
Purpose: BACPAC guidelines are similar to SUPAC but focus specifically on changes related to the active pharmaceutical ingredient (API) and its manufacturing process.
Content: Includes data on how changes in the API's manufacturing process may affect the drug's quality or performance.

Post-Marketing Surveillance
Once a drug is marketed, post-marketing surveillance (also known as Phase 4 studies) continues to monitor

its long-term safety and efficacy. This phase involves:

Adverse Event Reporting: Health professionals and consumers report adverse events (side effects) to regulatory agencies.

Risk Management: Identifying and managing risks associated with drug use, including rare side effects that may not have been detected in clinical trials.

Periodic Safety Update Reports (PSUR): Pharmaceutical companies are required to submit regular updates to regulatory bodies on the safety profile of the drug.

Product Registration Guidelines

CDSCO (Central Drugs Standard Control Organization - India)

- The CDSCO is the national regulatory body for pharmaceuticals and medical devices in India. The registration process includes the submission of an application containing detailed information about the drug's manufacturing, clinical trial data, safety profiles, and quality assurance measures.
- India follows strict guidelines for product registration under the Drugs and Cosmetics Act, with clear timelines and specific requirements for clinical trials and manufacturing documentation.

USFDA (United States Food and Drug Administration)

- The USFDA is the regulatory body responsible for the approval and regulation of drugs in the United States. The FDA requires detailed submissions for IND, NDA, ANDA, and other regulatory applications.
- The FDA ensures that drugs are safe and effective through a rigorous approval process, including evaluation of clinical trial data, manufacturing processes, and labeling.

INSTRUMENT HANDLING

Demonstration of TLC

1. Thin layer chromatography (TLC) is an important technique for identification and separation of mixtures of organic compounds it is useful in

- Identification of components of a mixture (using appropriate standard)
- Following the course of a reaction
- Analyzing fractions collected during purification
- Analyzing the purity of compound

2. In TLC, components are the mixture are partitioned between an absorbent (the stationary phase, usually silica gel , Sio_2) an a solvent (the mobile phase) which flows through the adsorbent . [24,25,26]

COMPONENTS OF TLC.

TLC plates: preferably ready made with a stationary phase:

These are stable and chemically inert plates, where a thin layer of stationary phase is applied on its whole surface layer. The stationary phase on the plates is of uniform thickness and is in a fine particle size.

TLC chamber: This is used for the development of TLC plate. The chamber maintains a uniform environment inside for proper development of spots. It also prevents the evaporation of solvents, and keeps the process dust free.

Mobile phase: This comprises of a solvent or solvent mixture The mobile phase used should be particulate-free and of the highest purity for proper development of TLC spots. The solvents recommended

are chemically inert with the sample, a stationary phase.



DEMONSTRATION OF UV VISIBLE SPECTROPHOTOMETER

Introduction

- A spectrophotometer is a photometer (a device for measuring light intensity) that can measure intensity as a function of the color (or more specifically the wavelength).
- UV-visible spectroscopy or UV-visible spectrophotometer involves the spectroscopy of photons in the UV - visible region. (200nm-400nm)
- This means it use light in the visible and adjacent (near ultraviolet and near infrared) range.

Application

1. Detection of functional group
2. Extent of conjugation
3. Identification of unknown compound
4. Elucidation of the structure of vitamins-
5. Qualitative analysis
6. Quantitative analysis
7. Detection of impurities[24,25,26,27]

DEMONSTRATION OF High Performance Liquid Chromatography (HPLC)

Introduction

HPLC is an extension of conventional liquid chromatography.

- Powerful tool in analytical techniques
- Columns are tightly packed, and the eluent is forced through the column under high pressure(up to 5,000 psi) by a pump.
- Allows to use a very smaller particle size for the column packing material which gives a much greater surface area for interactions between the stationary phase and the molecules flowing through it.
- Allows a much better separation of the components of the mixture. T T

Components of HPLC

Components of HPLC Pump Injector

1.Column 2. Detector 3.Recorder or data system[24,25,26,28]



DEMONSTRATION OF DISSOLUTION TEST APPARATUS:

INTRODUCTION

- Dissolution is a technique in which a solid substance solubilizes in a given solvent i.e. mass transfer from the solid surface to the liquid phase.
- Dissolution examination is a process which is used to measure the release profile of the drug from formulation which are commonly solid oral dosage form like tablets and capsules .
- Dissolution is a expressed in terms of a rate process if the rate increases the Dissolution process also increses Dissolution rate possibly defined as the amount of drug substance that enters solution per unit time below standardized experimental condition Noyes - Whitney's equation is valuable in estimation of rate of Dissolution The rate of Dissolution is describe as : $dc/dt = KS (Cs – C)$ [24,25,26,39]

Where:

K = Dissolution rate constant,

S = surface area of the particles,

Classification of Dissolution apparatus in different pharmacopeias:

	I.P	**USP**	**B.P**	**E.P**
Type 1	Paddle apparatus	Basket apparatus	Basket Apparatus	Paddle apparatus
Type 2	Basket apparatus	Paddle Apparatus	Paddle Apparatus	Basket Apparatus
Type 3	-	Reciprocating Cylinder	Flow through cell apparatus	Flow through cell apparatus
Type 4	Flow through Cell apparatus	Flow through cell apparatus	-	-
Type 5	-	Paddle over disc	-	-
Type 6	Cylinder	Cylinder	-	-
Type 7	Reciprocating holder	Reciprocating holder	-	-

DEMONSTRATION OF pH METER :

Introduction:

pH-Meter is capable of giving pH values of an acidic as well as alkaline samples. pH is a unit of measure which describes the degree of acidity or alkalinity (basic) of a solution. It is measured on a scale of 0 to 14. The formal definition of pH is the negative logarithm of the hydrogen ion activity.[34]

pH = -log[H+]

- A voltmeter in the probe measures the difference between the voltages of the two electrodes. The meter then translates the voltage difference into pH and displays it on the screen[24,25,26]
- The pH of a solution can be measured by the pH meter. The glass electrode is an half cell and the calomel electrode is another half



Validation

1. Introduction to the Concept of Validation

Validation is defined as "A Documented Programme , which Provides a high degree of assurance that a specific process will consistently produce a product meeting its predetermined Specifications and quality attributes".[31 32,33]

Definition of Calibration, Qualification, and Validation:

Calibration refers to the process of adjusting an instrument or device to ensure its accuracy by comparing it against a known standard. Calibration ensures that measurements taken by instruments are accurate within a defined tolerance.

Qualification is a series of activities to ensure that equipment, systems, or facilities meet predetermined specifications and perform consistently. It typically involves installation, operational, and performance qualification (IQ, OQ, PQ).

Validation is the process of ensuring that a system, process, or equipment consistently operates within predefined specifications and produces consistent results. Validation is crucial in regulated industries like pharmaceuticals to ensure compliance with regulatory standards (e.g., FDA, EMA). [33]

Scope, Frequency, and Importance:

The **scope** of validation is vast and includes systems, equipment, processes, and utilities that impact product quality and safety.

Frequency of validation depends on the type of equipment or process, regulatory requirements, and risk assessments. For instance, equipment might need to be validated annually or at intervals after specific maintenance or upgrades.

Importance: Validation is critical for ensuring product quality, regulatory compliance, and safety. It helps prevent errors, product recalls, and maintains consistency in manufacturing processes.

Calibration of Weights and Measures:

Calibration of weights and measures is essential for maintaining the accuracy of measurement devices used in manufacturing. Regular calibration ensures compliance with local regulatory standards and guarantees that the correct quantity of product is being manufactured or dispensed. [38]

2. Advantages of Validation

- Ensures Compliance
- Improves Product Quality
- Reduces Risk
- Enhances Efficiency

Scope of Validation:

Validation applies to equipment, systems, processes, and utilities that affect the quality of products. This includes manufacturing systems, analytical instruments, laboratory equipment, and utility systems.

Organization for Validation:

Validation teams typically include quality assurance (QA) specialists, engineers, and subject matter experts (SMEs) who collaborate to ensure validation is carried out effectively.

Validation Master Plan:

A **Validation Master Plan (VMP)** is a high-level document that outlines the approach, scope, and strategy for validation activities in an organization. It includes timelines, resources, and responsibilities for the validation of equipment, processes, systems, and utilities.

3. Types of Validation

Prospective Validation: Conducted before a process or system is implemented to ensure that it will function as expected.

Concurrent Validation: Conducted during the actual manufacturing process or system operation.

Retrospective Validation: Done for existing processes or systems based on historical data.

Revalidation: Performed periodically or after significant changes (e.g., equipment repairs or upgrades) to ensure systems or processes still meet specifications.[32]

Streamlining Qualification & Validation Process:

Streamlining involves reducing unnecessary steps, improving documentation, and using risk-based approaches to ensure efficient validation. It involves integrating qualification and validation activities and automating documentation wherever possible.

Validation Master Plan and Qualification: The **Validation Master Plan (VMP)** includes the detailed approach for qualification of systems and equipment. It is supported by specific qualification protocols for:

User Requirement Specification (URS): Defines user needs for the equipment or system.

Design Qualification (DQ): Verifies that the design meets URS and complies with industry regulations.

Installation Qualification (IQ): Ensures the system or equipment is installed according to specifications.

Operational Qualification (OQ): Confirms that the system operates as intended under normal conditions.

Performance Qualification (PQ): Ensures that the system consistently produces expected results under actual operating conditions.

Requalification: Requalification involves repeating the validation activities (IQ, OQ, PQ) if there are major changes to the system, equipment, or processes that may affect their performance.

4. Qualification of Manufacturing Equipment

The qualification of manufacturing equipment is an essential aspect of the validation process. Here are some common equipment types and their qualification steps:

Dry Powder Mixers: Ensure that the mixer meets specifications for homogeneity, consistency, and product quality. Qualification involves verifying that the mixer can achieve the desired mix uniformity within the specified time.

Tray Dryers: Ensure the dryer can maintain uniform temperature and humidity conditions. This is critical for ensuring consistent product drying and avoiding degradation.

Tablet Compression Machine: Validating the machine to ensure that it consistently produces tablets with the correct weight, hardness, and thickness.

Autoclaves: These are validated to ensure that sterilization cycles consistently achieve the desired temperature, pressure, and time for sterilizing pharmaceutical equipment or products.

Membrane Filtration: Ensures that the filtration system performs efficiently and consistently removes contaminants from water or other fluids.

Capsule Filling Machines: Qualification ensures the accurate filling of capsules with the correct dosage and consistency.

5. Qualification of Analytical Instruments

Analytical instruments are critical for testing and ensuring the quality of pharmaceutical products. The qualification of these instruments includes:

UV-Visible Spectrophotometer: Verifying that the instrument accurately measures absorbance or transmission across a specific wavelength range.

FTIR (Fourier Transform Infrared Spectroscopy): Ensuring that the FTIR system provides accurate spectral data for identifying chemical substances and confirming their identity and purity.

6. Qualification of Laboratory Equipment: Laboratory equipment is vital for testing the quality of pharmaceutical products. The qualification of these instruments includes the following:

Hardness Tester: Verifying that the tester accurately measures the hardness of tablets to ensure proper disintegration and dissolution.

Friability Test Apparatus: Ensuring that the instrument accurately measures the friability of tablets to test their resistance to mechanical stress during handling.

Tap Density Tester: Validating that the tester provides accurate measurements of bulk density and tapped density for powders and granular materials.

Disintegration Tester: Ensuring that the tester consistently measures the disintegration time of tablets as per regulatory standards.

Dissolution Test Apparatus: Verifying that the apparatus provides accurate dissolution profiles for tablets or capsules under controlled conditions.

7. Validation of Utility Systems

Utility systems are essential for maintaining the integrity of the manufacturing environment. Validation of these systems includes:

Pharmaceutical Water System & Pure Steam: Ensuring that the water system consistently delivers purified water or pure steam that meets required quality standards (e.g., USP, EP).

HVAC System (Heating, Ventilation, and Air Conditioning): Validation ensures that the HVAC system maintains the correct temperature, humidity, and airflow to meet the requirements for controlled environments (e.g., cleanrooms).

4. Process Validation : Process validation ensures that manufacturing processes, from raw material handling to final product packaging, consistently produce products that meet predetermined quality standards. It is a critical step in the pharmaceutical industry, as it demonstrates that a process is capable of consistently producing a product that meets its specifications.[32]

Types of Process Validation:

Prospective Validation:

- Prospective validation is conducted **before** the process is implemented or modified. This involves thorough planning and testing to ensure that the new process will consistently produce a product that meets the desired quality standards.
- It typically involves defining process parameters, determining critical process variables, and conducting trials or experiments to demonstrate process capability.
- **Key steps**: Protocol preparation, equipment qualification, process design, and trial batches. [32]

Concurrent Validation:

- Concurrent validation is performed **during** the actual operation of the process. In this approach, real-time data is collected and evaluated as the process is ongoing, often while manufacturing commercial batches.
- This type of validation helps ensure that the process is performing as expected during full-scale production, providing evidence of consistency and control.
- **Key steps**: Data collection during production runs, process monitoring, and batch documentation. [32]

Retrospective Validation:

- Retrospective validation involves evaluating **historical data** to confirm that a process consistently produces a product within the desired quality specifications. This method is used for existing processes where prospective validation was not initially conducted or where there have been significant changes.
- **Key steps**: Review of historical process data, batch records, and previous product performance. It may also involve conducting additional tests if required. [32]

Revalidation Criteria: Revalidation is necessary when changes are made to a process or when the process may have been affected by an external factor. Revalidation is triggered under the following circumstances:

- **Equipment modifications**: Changes in equipment that may affect the process (e.g., upgrade, replacement).
- **Process changes**: Modifications to raw materials, manufacturing procedures, or environmental conditions.
- **Regulatory changes**: Updates to regulations or standards that may impact process requirements.
- **Out-of-specification results**: If a process consistently produces products outside of acceptable quality limits.
- **Time intervals**: Periodic revalidation based on a predefined schedule to ensure ongoing compliance and process stability.

5. Analytical Method Validation

General Principles of Analytical Method Validation: Analytical method validation is the process of confirming that an analytical method is suitable for its intended purpose. This ensures that the method provides reliable, accurate, and consistent results under the conditions it is used. It is essential to validate analytical methods for both the release of raw materials and finished products, as well as during the stability studies of pharmaceutical products.

The general principles of analytical method validation include:

Specificity: The ability of the method to measure the analyte in the presence of other components in a sample.

Accuracy: The closeness of measured values to the true value or a standard reference.

Precision: The degree to which repeated measurements under the same conditions produce the same result.

Detection Limit: The smallest quantity of the analyte that can be reliably detected by the method.

Quantitation Limit: The lowest amount of the analyte that can be quantified with acceptable accuracy and precision.

Linearity: The ability of the method to produce results that are directly proportional to the concentration of the analyte within a given range.

Range: The interval between the upper and lower levels of analyte that can be determined with precision, accuracy, and linearity.

Analytical Method Validation as per ICH Guidelines (Q2): The **International Council for Harmonisation (ICH)** provides guidelines for the validation of analytical methods in the pharmaceutical industry, specifically **ICH Q2(R1)**: "Validation of Analytical Procedures: Text and Methodology". This guideline outlines the necessary tests for validating analytical methods, including:

Stability: Ensuring the stability of the analyte during analysis, including its stability in storage, in solutions, and during sample handling.

Robustness: The ability of the method to remain unaffected by small variations in method conditions (e.g., temperature, pH, solvents) and to provide reliable results under normal operating conditions.

System Suitability: Ensuring that the equipment, apparatus, and software used in the analysis are operating properly and providing consistent results. This includes checking for baseline stability, peak resolution, and reproducibility.

Analytical methods may include techniques such as HPLC, gas chromatography (GC), spectrophotometry, or mass spectrometry. Each of these methods needs to be validated according to the criteria laid out in the ICH guidelines.

6. Cleaning Validation: Cleaning validation ensures that cleaning procedures effectively remove residues of the drug product, contaminants, and cleaning agents from manufacturing equipment and surfaces. The objective is to confirm that equipment is thoroughly cleaned between batches, preventing cross-contamination, and ensuring product quality.[40]

Cleaning Method Development: Cleaning method development involves determining the most appropriate cleaning procedure for specific equipment or systems used in pharmaceutical manufacturing. This process typically includes:

Selection of Cleaning Agents: Identifying suitable solvents, detergents, or cleaning agents based on their ability to remove the active pharmaceutical ingredient (API), excipients, and other residues.

Cleaning Process Design: Developing procedures for manual or automated cleaning, including factors such as temperature, time, and solution concentration.
Risk Assessment: Identifying critical areas and potential risks for contamination, focusing on the worst-case scenario (i.e., the most difficult-to-clean equipment or product residues). [40]
Validation of Analytical Methods Used in Cleaning: Analytical methods used in cleaning validation ensure that cleaning agents and methods effectively remove residues and contaminants. These methods typically include:
Swab Sampling: Collecting samples from surfaces to analyze for traces of contaminants (e.g., API, excipients, detergents).
Rinse Sampling: Testing rinse water or solutions for residual contaminants after cleaning.
Types of Analytical Methods: Methods such as HPLC, UV-Visible spectroscopy, or ELISA (enzyme-linked immunosorbent assay) can be used to detect and quantify residues. [40]
Cleaning of Equipment: Cleaning of equipment is critical to ensure that no residue from the previous batch of product contaminates the subsequent batch. Steps involved in cleaning equipment validation include:
Equipment Design Considerations: Ensuring that equipment is designed to facilitate cleaning and prevent contamination (e.g., using materials that are easy to clean, eliminating hard-to-reach areas).
Cleaning Procedures: Developing and documenting cleaning procedures that ensure effective removal of residues, considering factors such as cleaning time, temperature, and cleaning agent concentration.
Verification: Using appropriate analytical methods to confirm that cleaning procedures are effective and that residue levels are within acceptable limits. [40]
Cleaning of Facilities: Just as equipment needs to be thoroughly cleaned, the facilities where manufacturing takes place must also be validated to ensure cleanliness and avoid contamination. This includes cleaning of rooms, floors, walls, ventilation systems, and any other parts of the facility where contaminants might accumulate.
Environmental Monitoring: Regular monitoring of cleanroom environments for microbial contamination and particle counts.
Disinfection Procedures: Establishing disinfection procedures for surfaces, air, and water systems to maintain cleanliness. [40]

1. Introduction to Quality by Design (QbD)

Quality by Design (QbD) is a systematic approach to pharmaceutical development that emphasizes the design of quality into the product and the process from the beginning. The primary goal of QbD is to ensure that quality is not merely tested at the end of the manufacturing process but is built into it from the start. By understanding the relationship between raw materials, process parameters, and product attributes, QbD ensures the product meets predefined quality criteria.[41]

Process Analytical Technology (PAT)

Process Analytical Technology (PAT) complements QbD by utilizing real-time data and monitoring tools to control the manufacturing process. PAT enables continuous assessment of the process and product quality during production, facilitating early detection of issues and adjustments before they affect the final product. Both QbD and PAT are critical for improving product consistency, reducing costs, and accelerating time-to-market.

2. Auditing in the Drug Industry

Audits in the pharmaceutical industry are essential for ensuring compliance with regulatory standards and maintaining the quality of products. The audit process involves a comprehensive evaluation of an organization's operations to ensure that they meet both internal and external requirements.

Objectives of Auditing

- To evaluate compliance with legal and regulatory standards.
- To identify areas of risk or non-compliance.
- To assess the effectiveness of current quality systems.
- To ensure products are safe and meet quality standards.

Management of Audit

Auditing involves careful planning, organization, and the allocation of responsibilities to ensure that the audit is thorough and unbiased. Effective management of audits includes setting clear objectives, selecting qualified auditors, and following structured audit protocols.

Responsibilities

- **Auditors**: Conduct thorough investigations, document findings, and provide recommendations.
- **Management**: Ensure corrective actions are taken in response to audit findings, ensuring continuous improvement.
- **Regulatory Bodies**: Oversee audits to ensure they align with industry standards and regulations.

Planning the Audit

The audit process starts with planning, including defining the scope, establishing timelines, and selecting audit teams. This phase also involves determining the objectives and focusing areas, such as GMP (Good Manufacturing Practice) compliance or product quality.

Information Gathering

Information gathering involves reviewing records, interviewing key personnel, and observing processes. Auditors collect both qualitative and quantitative data to evaluate compliance.

Classifications of Deficiencies

Deficiencies found during audits are typically classified based on severity:

- **Critical**: Immediate action required to address a serious issue affecting product safety or regulatory compliance.
- **Major**: Significant non-compliance that may lead to future problems if not corrected.
- **Minor**: Less serious issues that require attention but do not pose an immediate risk.

Audit Checklist for Drug Industries

An audit checklist is used to ensure that all critical aspects of the audit are covered. This includes areas like:

- GMP compliance.
- Equipment calibration and maintenance.
- Documentation practices.
- Employee training and qualifications
- **Introduction, Scope, and Importance of Intellectual Property Rights (IPR):**Intellectual Property Rights (IPR) are legal protections granted to creators and innovators for their intellectual creations, such as inventions, designs, and works of art. IPR is crucial in fostering innovation by providing

inventors with exclusive rights to their creations, thereby encouraging further research and development.

Concepts of IPR:

Trademarks: Protect unique symbols, names, or logos that distinguish goods or services in the marketplace.

Copyright: Protect original works of authorship, such as books, music, or software, from unauthorized use.

Patents: Grant exclusive rights to inventors for a limited time, typically 20 years, to produce and sell their inventions.

Importance of IPR

Encourages Innovation: Provides financial incentives for research and development

Protects Market Position: Safeguards the unique selling propositions of businesses and individuals.

Enhances Global Competitiveness: Ensures that innovations are recognized and protected internationally.

Prevents Infringement: Legal enforcement of IP rights helps prevent unauthorized duplication or use of proprietary technologies.

References

1. WHO. Quality Assurance of Pharmaceuticals; VOL-1, Indian Edition, Delhi, AITBS Publishers & Distributions, 2007, page no.86-96
2. Potdar, Mr Manohar A. *Pharmaceutical quality assurance*. Pragati Books Pvt. Ltd., 2006.
3. Koc, T., 2007. The impact of ISO 9000 quality management systems on manufacturing. *Journal of materials processing technology*, *186*(1-3), pp.207-213.
4. https://link.springer.com/book/9789401176903
5. http://www.iso.org/iso/home/standards/management-standards/iso_9000.htm
6. https://www.ich.org/page/quality-guidelines
7. https://www.ich.org/page/safety-guidelines
8. https://www.ich.org/page/efficacy-guideline
9. https://www.ich.org/page/multidisciplinary-guidelines
10. ISO 9001:2015: Quality management standards applicable to pharmaceutical Warehousing
11. USP Chapter <711> (Dissolution)
12. Indian Pharmacopoeia Commission. (2018). **Indian Pharmacopoeia 2018**. Volume 1. Government of India. Ministry of Health & Family Welfare. Section on Tablets (Page 1224) and Capsules (Page 1243). ISBN: 978-81-907799-2-2.
13. U.S. Pharmacopeial Convention. (2020). **USP 43-NF 38: Uniformity of Dosage Units**. United States Pharmacopeia, 905. Rockville, MD: United States Pharmacopeial Convention. ISBN: 978-1-3993-7274-7.
14. https://www.fda.gov/media/82539/download
15. Indian Pharmacopoeia. The Controller of publication, New Delhi; Ministry of Health and Family welfare.Volume I. India 5th edition, particulate contamination. (2007) 28,54,182,187,188-190

16. . Monappa R. Sutar, Deepali R. Gawhane, C.R.Tenpe, "Study of Drug Regulatory Approval Process and Comparative Requirement of Common Technical Documents (CTD) in Europe, USA and India in Coordination with Drug Developmental Process"" Int. J. Pharm. Sci. Rev. Res., 2013; 20(2): 68-79.
17. ShivamLale,Amol Kendre,Mayur Gandhi,Shreyas Dani; "Role of Drug Regulatory Affairs in pharma Industry",World Journal of Pharmaceutical Research; Volume 4,Issue6, 615-625
18. European Union Guidelines for Good Distribution Practice of Medicinal Products for Human Use**: Standards for the EU pharmaceutical market.
19. http://thepharmacistpharma.blogspot.in/2009/03/evaluation-of-ointments.html?m=1
20. WHO Country Office for India, Department of Pharmaceuticals, FICCI. India Pharma Summit 2014-15. Policy Landscape Reforms for Strengthening Indian Pharmaceutical Industry. Position Paper. 2015.
21. https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/regulatory-standards/trs1010-annex11.pdf?sfvrsn=b7c8b9c1_2
22. https://www.tga.gov.au/tga-regulatory-framework
23. **https://www.ich.org/page/ctd**
24. **Instrumentation By B. K. Sharma.**
25. **Biophysical Chemistry by Upadhyay & Upadhyay Nath.**
26. **instrumental methods of chemical analysis by chatwal.**
27. **http://scimedia.com**
28. **http://www.forumsci.co.il/HPLC**
29. Brahmankar et al.1995
30. SubrahmanyamC.V.S,et al.,2008
31. PotdarManohar A. "Pharmaceutical quality assurance" 2nd Edition, Nirali Prakashan, p-8.1-8.7
32. Nash Robert A. "Pharmaceutical Process Validation"3rd Edition, Marcel Dekker Inc, p-442
33. Cole Graham C. 'Pharmaceutical Production Facilities" 2nd Edition, CRC Press, p-199 4. Despautz Joseph F.
34. Walker John, (2008), pH and oxygen electrodes, Principles and Techniques of Biochemistry and Molecular Biology, Cambridge University Press, 6th edition
35. .http://en.wikipedia.org/wiki/PH_meter
36. Read more at: https://www.pharmaguideline.com/2019/03/validation-of-utilitysystems.html?m=1 Validation is the process of evaluating products or analytical Methods to ensure compliance with products or cleaning Method requirements
37. Dr. Keyur B. Ahir, Khushboo D. Singh, Sushma P. Yadav, Hetal S. Patel, Chetan B. Poyahari, Overview of Validation and Basic Concepts of Process Validation ,Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2014; 3(2): 178-190
38. Laura T U H Melero, Kátia S. Da S. Silva, Camila Zanette, Elaine B. De Araújo, Jair Mengatti. Calibration and Qualification of Equipments in the Pharmaceutical Industry: Emphasis on Radiopharmaceuticals Production, International Nuclear Atlantic Conference. 2011; Belo Horizonte, MG, Brazil.
39. Kulkarni S.Bairagee D.Mishra s. Verma AR. Qualifications of Autosampter dissolution test apparatus Type I & Type II
40. S.W.Harder "The validation of cleaning process " pharmaceutical technology. 8(5),29,34(1984) .
41. Amit S. Patil, Anil M. Pethe Quality by Design (QBD): A new concept for development of quality pharmaceuticals review article international journal of quality assurance 4(2), 17-18.